BMT CTN Protocol 0401 -- Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

Below are protocol-related doucments, which may be periodically updated.

• Protocol synopsis, version 6.0 dated December 27, 2007
• Protocol, version 6.0 dated December 27, 2007
• Summary of protocol changes (version 5.0 to 6.0)
• Informed consent, version 6.0 dated December 27, 2007
• Educational Material
• Informational Flyer
• Participating Centers
• Key Personnel

            Protocol Chair: Julie Vose, MD (402-559-3848) jmvose@unmc.edu

            Protocol Officer: Marcie Tomblyn, MD (612-624-5109) tombl001@umn.edu

            Protocol Coordinator: Jennierose D’Elia (301-251-1161) jdelia@emmes.com

            Medical Monitor: Mary Eapen, MD (414-456-4606) meapen@mcw.edu

The BMT CTN is committed to including widespread transplant community participation in these trials.  However, due to the limited resources, not all requests can be accommodated for each protocol.  If your center is interested in participating, please  fax the completed Affiliate Center Application, or you may complete the short form if currently participating as an affiliate center in any other BMT CTN trial, to BMT CTN DCC/EMMES at 301-251-1355.  You will be contacted if your center is selected for participation. 

If you have completed an application and want to inquire about your site’s participation status, please e-mail us.